Clinical Trial Update: Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating pirfenidone in young patients with Neurofibromatosis Type 1 and plexiform neurofibromas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neurofibromatosis Type 1, Precancerous Condition | Phase 1 | Status: COMPLETED